Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

See How to

Filter conferences

 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
      
      
 
      
 
      
      
      
      
      
      
      
      
      
      
PI3K Pathways Digital Summit

PI3K Pathways Digital Summit

Categories

Date of beginning

Friday, 28 August 2020

Duration

1 day

City

Online

Contact

Customer Service

E-Mail

This email address is being protected from spambots. You need JavaScript enabled to view it.

Memo

The PI3K Pathways Digital Summit will share the field's cutting-edge scientific advances, with a focus on oncology, enabling you to advance your clinical pipeline. Attend this virtual meeting to discuss novel, cutting edge PI3K inhibitors; share strategies to overcome toxicity and gain an update of the clinical landscape. Whether you're part of a PI3K-focused biotech, a pharmaceutical organization assessing this exciting field, or an academic researcher with breakthrough findings, join the PI3K Pathways Digital Summit as we explore the global advances in PI3K and AKT pathways, and meet like-minded peers who are continuing to understand the mechanistic, preclinical and clinical implication of PI3K in oncology and beyond. URLs:Tickets: https://go.evvnt.com/663966-2?pid=5569Brochure: https://go.evvnt.com/663966-3?pid=5569 Price:Conference Ticket (1st Release): USD 1200.0 Speakers: Christian Ottensmeier, Professor - Experimental Cancer Medicine, University of Southampton, Ningshu Liu, Head of Laboratory Immuno Oncology and Senior Director and Global Strategy Lead, Bayer, William Kerr, Empire Scholar and Professor - Microbiology and Immunology Children's Oncology Research Pediatrics, State University of New York Upstate Medical University, Harish Dave, Co-Founder Chief Medical Officer, AUM Biosciences, Murray Yule, Chief Medical Officer, Inflection Biosciences, Igor Vivanco, Team Leader - Molecular Addictions, Institute of Cancer Research, Ralitsa Madsen, Research Fellow, University College London, Zoe Johnson, Chief Scientific Officer, iOnctura, Teresa Gagliano, Senior Scientist, University of Zurich, Bart Vanhaesebroeck, Professor - Cell Signalling, University College London, Thomas Rossi, CEO, Venthera, Kathy Gately, Senior Lecturer - Clinical, Trinity College Dublin, Jennifer Brown, Assistant Professor, Dana-Farber Cancer Institute, James Garner, Chief Executive Officer and Managing Director, Kazia therapeutics, Alessio Fiascarelli, Research Scientist, Menarini Group, Nishan Rajakumaraswamy, Director Clinical Research Oncology/ Hematology, Gilead Sciences, Anwesha Dey, Project Team Leader and Senior Scientist, Genentech, Cornelia Quadt, Sr. Clinical Program Leader Translational Clinical Oncology, Novartis Time: 10:00 - 19:00